Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients

Peptides

Volumn 31, Issue 4, 2010, Pages 603-608

  Burian, Bernhard ^a   Storka, Angela ^a   Marzluf, Beatrice A ^a   Yen, Yong Cheng ^b   Lambers, Christopher ^a   Robibaro, Bruno ^a   Vonbank, Karin ^a   Mosgoeller, Wilhelm ^b   Petkov, Ventzislav ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti inflammatory therapy; Interleukin 8; Macrophages; Vasoactive intestinal peptide

Indexed keywords

INTERLEUKIN 8; LIPOPOLYSACCHARIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS MACROPHAGE; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; VOLUNTEER;

AGED; ANIMALS; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; LUNG; MACROPHAGES; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; SIGNAL TRANSDUCTION;

EID: 77649232716     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.12.014     Document Type: Article

References (46)

1. Arranz A., Abad C., Juarranz Y., Leceta J., Martinez C., and Gomariz R.P. Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 15 (2008) 46-53
2. Arranz A., Gutierrez-Canas I., Carrion M., Juarranz Y., Pablos J.L., Martinez C., et al. VIP reverses the expression profiling of TLR4-stimulated signaling pathway in rheumatoid arthritis synovial fibroblasts. Mol Immunol 45 (2008) 3065-3073
3. Barnes P.J., Shapiro S.D., and Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22 (2003) 672-688
4. Belvisi M.G., and Bottomley K.M. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?. Inflamm Res 52 (2003) 95-100
5. Busto R., Prieto J.C., Bodega G., Zapatero J., and Carrero I. Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides 21 (2000) 265-269
6. Chen G., Hao J., Xi Y., Wang W., Wang Z., Li N., et al. The therapeutic effect of vasoactive intestinal peptide on experimental arthritis is associated with CD4+CD25+ T regulatory cells. Scand J Immunol 68 (2008) 572-578
7. Chorny A., and Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 172 (2008) 1297-1307
8. Choudhuri U., Adams J.A., Byrom N., McCarthy D.M., and Barrett J. 1,25-Dihydroxyvitamin D3 induces normal mononuclear blood cells to differentiate in the direction of monocyte-macrophages. Haematologia (Budap) 23 (1990) 9-19
9. Chung K.F., and Adcock I.M. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 31 (2008) 1334-1356
10. Delgado M., Abad C., Martinez C., Leceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7 (2001) 563-568
11. Delgado M., Martinez C., Johnson M.C., Gomariz R.P., and Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 68 (1996) 27-38
12. Dey R.D., Shannon Jr. W.A., and Said S.I. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res 220 (1981) 231-238
13. Fromer L., and Cooper C.B. A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD. Int J Clin Pract 62 (2008) 1219-1236
14. Fuss I.J., Kanof M.E., Smith P.D., and Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol (2009) [Chapter 7: Unit7.1]
15. Ghatei M.A., Sheppard M.N., O'Shaughnessy D.J., Adrian T.E., McGregor G.P., Polak J.M., et al. Regulatory peptides in the mammalian respiratory tract. Endocrinology 111 (1982) 1248-1254
16. Gomariz R.P., Arranz A., Juarranz Y., Gutierrez-Canas I., Garcia-Gomez M., Leceta J., et al. Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides 28 (2007) 1825-1832
17. Groneberg D.A., Hartmann P., Dinh Q.T., and Fischer A. Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways. Lab Invest 81 (2001) 749-755
18. Groneberg D.A., Rabe K.F., and Fischer A. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 533 (2006) 182-194
19. Groneberg D.A., Springer J., and Fischer A. Vasoactive intestinal polypeptide as mediator of asthma. Pulm Pharmacol Ther 14 (2001) 391-401
20. Hajos F., Stark B., Hensler S., Prassl R., and Mosgoeller W. Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm 357 (2008) 286-294
21. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 2645-2653
22. Ishihara T., Shigemoto R., Mori K., Takahashi K., and Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8 (1992) 811-819
23. Johansson M., Jonsson M., Norrgard O., and Forsgren S. New aspects concerning ulcerative colitis and colonic carcinoma: analysis of levels of neuropeptides, neurotrophins, and TNFalpha/TNF receptor in plasma and mucosa in parallel with histological evaluation of the intestine. Inflamm Bowel Dis 14 (2008) 1331-1340
24. Laitinen A., Partanen M., Hervonen A., Pelto-Huikko M., and Laitinen L.A. VIP like immunoreactive nerves in human respiratory tract. Light and electron microscopic study. Histochemistry 82 (1985) 313-319
25. Lapperre T.S., Willems L.N., Timens W., Rabe K.F., Hiemstra P.S., Postma D.S., et al. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD. Chest 131 (2007) 53-59
26. Linden A., Hansson L., Andersson A., Palmqvist M., Arvidsson P., Lofdahl C.G., et al. Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma. Thorax 58 (2003) 217-221
27. Litwin D.K., Wilson A.K., and Said S.I. Vasoactive intestinal polypeptide (VIP) inhibits rat alveolar macrophage phagocytosis and chemotaxis in vitro. Regul Pept 40 (1992) 63-74
28. Lucchini R.E., Facchini F., Turato G., Saetta M., Caramori G., Ciaccia A., et al. Increased VIP-positive nerve fibers in the mucous glands of subjects with chronic bronchitis. Am J Respir Crit Care Med 156 (1997) 1963-1968
29. Mahler D.A., Huang S., Tabrizi M., and Bell G.M. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 126 (2004) 926-934
30. Martinez C., Juarranz Y., Abad C., Arranz A., Miguel B.G., Rosignoli F., et al. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock. J Leukoc Biol 77 (2005) 729-738
31. Miotto D., Boschetto P., Bononi I., Zeni E., Cavallesco G., Fabbri L.M., et al. Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis. Eur Respir J 24 (2004) 958-963
32. Mosgoeller W., Kastner P., Fang-Kircher S., Kitzmueller E., Hoeger H., Seither P., et al. Brain RNA polymerase and nucleolar structure in perinatal asphyxia of the rat. Exp Neurol 161 (2000) 174-182
33. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 (1997) 1498-1504
34. Onoue S., Ohmori Y., Endo K., Yamada S., Kimura R., and Yajima T. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur J Biochem 271 (2004) 1757-1767
35. Palmer J.B., Cuss F.M., Warren J.B., Blank M., Bloom S.R., and Barnes P.J. Effect of infused vasoactive intestinal peptide on airway function in normal subjects. Thorax 41 (1986) 663-666
36. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111 (2003) 1339-1346
37. Said S.I. Vasoactive intestinal polypeptide (VIP): current status. Peptides 5 (1984) 143-150
38. Sarir H., Henricks P.A., van Houwelingen A.H., Nijkamp F.P., and Folkerts G. Cells, mediators and Toll-like receptors in COPD. Eur J Pharmacol 585 (2008) 346-353
39. Sergejeva S., Hoshino H., Yoshihara S., Kashimoto K., Lotvall J., and Linden A. A synthetic VIP peptide analogue inhibits neutrophil recruitment in rat airways in vivo. Regul Pept 117 (2004) 149-154
40. Shapiro S.D. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999) S29-32
41. Szema A.M., Hamidi S.A., Lyubsky S., Dickman K.G., Mathew S., Abdel-Razek T., et al. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 291 (2006) L880-L886
42. Tetley T.D. Inflammatory cells and chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy 4 (2005) 607-618
43. Tumkaya M., Atis S., Ozge C., Delialioglu N., Polat G., and Kanik A. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med 101 (2007) 729-737
44. Usdin T.B., Bonner T.I., and Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135 (1994) 2662-2680
45. Yang J.Q., Rudiger J.J., Hughes J.M., Goulet S., Gencay-Cornelson M.M., Borger P., et al. Cell density and serum exposure modify the function of the glucocorticoid receptor C/EBP complex. Am J Respir Cell Mol Biol 38 (2008) 414-422
46. Yin H., Cheng H., Yu M., Zhang F., Lin J., Gao Y., et al. Vasoactive intestinal peptide ameliorates synovial cell functions of collagen-induced arthritis rats by down-regulating NF-kappaB activity. Immunol Invest 34 (2005) 153-169